CORD-19:68a7101a90454172c91785d8c352f776a82df5d4 / 513610-513993 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T1043","span":{"begin":0,"end":383},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ELND002 is a potent inhibitor of a4 integrin-mediated human leukocyte adhesion in vitro Garrido Caroline, Mao Jennifer, Xu Yi-Zheng, Nguyen Van, Yednock Ted, Bard Frédérique Elan Pharmaceuticals, South San Francisco, United States ELND002 is a potent and selective pegylated small molecule alpha-4 integrin inhibitor currently being evaluated for the treatment of multiple sclerosis."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T122","span":{"begin":0,"end":383},"obj":"Sentence"}],"text":"ELND002 is a potent inhibitor of a4 integrin-mediated human leukocyte adhesion in vitro Garrido Caroline, Mao Jennifer, Xu Yi-Zheng, Nguyen Van, Yednock Ted, Bard Frédérique Elan Pharmaceuticals, South San Francisco, United States ELND002 is a potent and selective pegylated small molecule alpha-4 integrin inhibitor currently being evaluated for the treatment of multiple sclerosis."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T3288","span":{"begin":364,"end":382},"obj":"Disease"},{"id":"T54324","span":{"begin":364,"end":382},"obj":"Disease"}],"attributes":[{"id":"A3288","pred":"mondo_id","subj":"T3288","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A37087","pred":"mondo_id","subj":"T54324","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"}],"text":"ELND002 is a potent inhibitor of a4 integrin-mediated human leukocyte adhesion in vitro Garrido Caroline, Mao Jennifer, Xu Yi-Zheng, Nguyen Van, Yednock Ted, Bard Frédérique Elan Pharmaceuticals, South San Francisco, United States ELND002 is a potent and selective pegylated small molecule alpha-4 integrin inhibitor currently being evaluated for the treatment of multiple sclerosis."}